Aethlon Medical Appoints Dr. Kenneth R. Michael As Regulatory and Clinical Affairs Advisor.

Business Editors and Health/Medical Writers

LA JOLLA, Calif.--(BW HealthWire)--Aug. 8, 2002

Aethlon Medical Inc. (OTCBB:AEMD) announced today that Dr. Kenneth R. Michael has been appointed as a regulatory and clinical affairs advisor to the company.

Dr. Michael is the former vice president of Regulatory Affairs and Quality Assurance at Siemens Medical Systems, and is the founder, past president and chairman of The Regulatory Affairs Professionals Society (RAPS), an international professional society representing over 8,000 healthcare Regulatory Affairs professionals. He is also the founder of the local San Diego Regulatory Affairs Network (SDRAN). Currently, Dr. Michael serves as the president of KRM Associates LLC, a regulatory and clinical affairs consulting organization, and frequently teaches regulatory, quality and management professionals at various university and medical institutions. He is an active director of several medical device, and pharmaceutical organizations.

James A. Joyce, chairman and CEO of Aethlon Medical, stated, "Dr. Michael has a proven record of guiding medical device companies through the regulatory process. We certainly believe his experience and expertise will benefit our efforts to achieve market clearance for AEMD-45 and our other viral Hemopurifiers."

About Aethlon Medical

Aethlon Medical develops therapeutic devices that treat HIV/AIDS, Hepatitis-C, and other infectious diseases. In pre-clinical testing, Aethlon's lead product, AEMD-45 removes 55% of HIV from human blood in three hours and in excess of 85% in twelve hours. The AEMD-45 therapeutic device, like all product offerings from Aethlon Medical, is developed from an expansive platform technology known as the Hemopurifier(TM), which employs a proprietary method to increase the capability of FDA cleared artificial kidneys (hemodialysis cartridges) to remove targeted intoxicants from the blood. In the case of AEMD-45, dialysis cartridges are modified to mimic the immune system's response to clear infectious virus from circulation before healthy cells are infected. AEMD-45 is designed to fill the urgent need for new treatments that are effective in reducing viral load, decrease the likelihood of treatment resistance, and treat without the toxic side-effects associated with AIDS drugs. For more information, visit the company's Web site at www.AethlonMedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the company's ability to raise capital when needed, the company's ability to complete the development of its planned products, the ability of the company to obtain FDA and other regulatory approvals permitting the sale of its products, the company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the company's Securities and Exchange Commission filings.